Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:


This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Latest Financial Results

Q3 2023

Quarter Ended Sep 30, 2023

Latest 10-K

Fiscal Year Ended Dec 31, 2022

View Latest 10-K

Stock Information

Company Overview

Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety with fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and develops PDCs independently and through research and development collaborations.

The company’s product pipeline includes iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs, and multiple partnered PDC assets. The company is currently investigating iopofosine in a global, open-label, pivotal expansion cohort in relapsed or refractory WM patients who have received at least two prior lines of therapy, including those who have failed or had a suboptimal response to Bruton tyrosine kinase inhibitors. The WM cohort is designed to evaluate the efficacy and safety of iopofosine for marketing approval. The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with brain tumors in the Phase 1 CLOVER-2 study.

The Phase 1 pediatric study is an open-label, dose-finding study to evaluate the activity and safety of different dosages and dosing regimens of iopofosine in children and adolescents with relapsed or refractory brain tumors. The study is being conducted in up to fifteen leading pediatric cancer centers in North America.

The company has established exclusivity on a broad U.S. and international intellectual property rights portfolio around its proprietary cancer-targeting PLE technology platform, including iopofosine and its PDC programs.

In addition to the company’s exclusivity to iopofosine and its phospholipid ethers conjugated to small molecules, peptides, and oligos, the company now has non-exclusive rights to the use of the phospholipid ether platform when conjugating with a chelator to bind select metal radioisotopes.

For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: X (Twitter), LinkedIn, Facebook, Instagram, and YouTube.

Corporate Presentation - February 2024

Corporate Presentation - February 2024

Download Now

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
investors@cellectar.com

Investor Relations

Investor Contact
investors@cellectar.com

Business Development

Contact Information
businessdevelopment@cellectar.com

Transfer Agent

Equiniti Trust Company, LLC
Tamara Cajuste
48 Wall Street, Floor 23
New York, NY 10005
T: 718-921-8300 ext. 6462
M: 347-939-9659
F: 718-765-8712
Tamara.Cajuste@equiniti.com

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.